Detection of lysyl oxidase-like 2 (LOXL2), a biomarker of metastasis from breast cancers using human blood samples

Metini Janyasupab, Ying Hui Lee, Yuan Zhang, Chen W. Liu, Jieyi Cai, Adriana Popa, Anna C. Samia, Kuan W. Wang, Jiaqiang Xu, Chi Chang Hu, Michael K. Wendt, Barbara J. Schiemann, Cheryl L. Thompson, Yun Yen, William P. Schiemann, Chung C. Liu

研究成果: 雜誌貢獻文章

7 引文 (Scopus)

摘要

Metastasis accounts for 90% of the mortality associated with breast cancer. Upregulated expression of members of the lysyl oxidase (LOX) family of secreted copper amine oxidases catalyzes the crosslinking of collagens and elastin in the extracellular matrix. LOXs are linked to the development and metastatic progression of breast cancers. Accordingly, aberrant expression of LOX-like 2 (LOXL2) is observed in poorly differentiated, high-grade tumors and is predictive of diseases recurrence, and for decreased overall patient survival. Therefore, LOXL2 expression may serve as a biomarker for breast cancer. Mechanistically, hydrogen peroxide is produced as a byproduct of LOXL2 when using an appropriate substrate, lysine. We exploited this chemistry to generate a revolutionary gold-based electrochemical biosensor capable of accurately detecting nanomolar quantities of LOXL2 in mouse blood, and in human blood samples. Two different sources of the blood samples obtained from breast cancer patients were used in this study indicating the applicability of detecting LOXL2 in breast cancers patients. Limited numbers of urine specimens from breast cancer patients were also tested. Collectively, all of these tests show the promise and potential of this biosensor for detecting LOXL2 as a surrogate biomarker of breast cancer. This work is described in patent number WO2014052962 (2014).
原文英語
頁(從 - 到)93-100
頁數8
期刊Recent Patents on Biomarkers
5
發行號2
出版狀態已發佈 - 八月 1 2015

指紋

Protein-Lysine 6-Oxidase
Biomarkers
Blood
Breast Neoplasms
Neoplasm Metastasis
Biosensing Techniques
Biosensors
Amine Oxidase (Copper-Containing)
Elastin
Gold
Crosslinking
Hydrogen Peroxide
Lysine
Extracellular Matrix
Byproducts
Tumors
Collagen
Urine
Recurrence
Survival

ASJC Scopus subject areas

  • Molecular Medicine
  • Clinical Biochemistry

引用此文

Janyasupab, M., Lee, Y. H., Zhang, Y., Liu, C. W., Cai, J., Popa, A., ... Liu, C. C. (2015). Detection of lysyl oxidase-like 2 (LOXL2), a biomarker of metastasis from breast cancers using human blood samples. Recent Patents on Biomarkers, 5(2), 93-100.

Detection of lysyl oxidase-like 2 (LOXL2), a biomarker of metastasis from breast cancers using human blood samples. / Janyasupab, Metini; Lee, Ying Hui; Zhang, Yuan; Liu, Chen W.; Cai, Jieyi; Popa, Adriana; Samia, Anna C.; Wang, Kuan W.; Xu, Jiaqiang; Hu, Chi Chang; Wendt, Michael K.; Schiemann, Barbara J.; Thompson, Cheryl L.; Yen, Yun; Schiemann, William P.; Liu, Chung C.

於: Recent Patents on Biomarkers, 卷 5, 編號 2, 01.08.2015, p. 93-100.

研究成果: 雜誌貢獻文章

Janyasupab, M, Lee, YH, Zhang, Y, Liu, CW, Cai, J, Popa, A, Samia, AC, Wang, KW, Xu, J, Hu, CC, Wendt, MK, Schiemann, BJ, Thompson, CL, Yen, Y, Schiemann, WP & Liu, CC 2015, 'Detection of lysyl oxidase-like 2 (LOXL2), a biomarker of metastasis from breast cancers using human blood samples', Recent Patents on Biomarkers, 卷 5, 編號 2, 頁 93-100.
Janyasupab, Metini ; Lee, Ying Hui ; Zhang, Yuan ; Liu, Chen W. ; Cai, Jieyi ; Popa, Adriana ; Samia, Anna C. ; Wang, Kuan W. ; Xu, Jiaqiang ; Hu, Chi Chang ; Wendt, Michael K. ; Schiemann, Barbara J. ; Thompson, Cheryl L. ; Yen, Yun ; Schiemann, William P. ; Liu, Chung C. / Detection of lysyl oxidase-like 2 (LOXL2), a biomarker of metastasis from breast cancers using human blood samples. 於: Recent Patents on Biomarkers. 2015 ; 卷 5, 編號 2. 頁 93-100.
@article{e747d687414247648de6f388339bc5b5,
title = "Detection of lysyl oxidase-like 2 (LOXL2), a biomarker of metastasis from breast cancers using human blood samples",
abstract = "Metastasis accounts for 90{\%} of the mortality associated with breast cancer. Upregulated expression of members of the lysyl oxidase (LOX) family of secreted copper amine oxidases catalyzes the crosslinking of collagens and elastin in the extracellular matrix. LOXs are linked to the development and metastatic progression of breast cancers. Accordingly, aberrant expression of LOX-like 2 (LOXL2) is observed in poorly differentiated, high-grade tumors and is predictive of diseases recurrence, and for decreased overall patient survival. Therefore, LOXL2 expression may serve as a biomarker for breast cancer. Mechanistically, hydrogen peroxide is produced as a byproduct of LOXL2 when using an appropriate substrate, lysine. We exploited this chemistry to generate a revolutionary gold-based electrochemical biosensor capable of accurately detecting nanomolar quantities of LOXL2 in mouse blood, and in human blood samples. Two different sources of the blood samples obtained from breast cancer patients were used in this study indicating the applicability of detecting LOXL2 in breast cancers patients. Limited numbers of urine specimens from breast cancer patients were also tested. Collectively, all of these tests show the promise and potential of this biosensor for detecting LOXL2 as a surrogate biomarker of breast cancer. This work is described in patent number WO2014052962 (2014).",
keywords = "Biomarker, Lysyl oxidase-like 2 (LOXL2), Metastasis of breast cancers, Thin gold film biosensor",
author = "Metini Janyasupab and Lee, {Ying Hui} and Yuan Zhang and Liu, {Chen W.} and Jieyi Cai and Adriana Popa and Samia, {Anna C.} and Wang, {Kuan W.} and Jiaqiang Xu and Hu, {Chi Chang} and Wendt, {Michael K.} and Schiemann, {Barbara J.} and Thompson, {Cheryl L.} and Yun Yen and Schiemann, {William P.} and Liu, {Chung C.}",
year = "2015",
month = "8",
day = "1",
language = "English",
volume = "5",
pages = "93--100",
journal = "Current Biomarkers",
issn = "2468-4228",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Detection of lysyl oxidase-like 2 (LOXL2), a biomarker of metastasis from breast cancers using human blood samples

AU - Janyasupab, Metini

AU - Lee, Ying Hui

AU - Zhang, Yuan

AU - Liu, Chen W.

AU - Cai, Jieyi

AU - Popa, Adriana

AU - Samia, Anna C.

AU - Wang, Kuan W.

AU - Xu, Jiaqiang

AU - Hu, Chi Chang

AU - Wendt, Michael K.

AU - Schiemann, Barbara J.

AU - Thompson, Cheryl L.

AU - Yen, Yun

AU - Schiemann, William P.

AU - Liu, Chung C.

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Metastasis accounts for 90% of the mortality associated with breast cancer. Upregulated expression of members of the lysyl oxidase (LOX) family of secreted copper amine oxidases catalyzes the crosslinking of collagens and elastin in the extracellular matrix. LOXs are linked to the development and metastatic progression of breast cancers. Accordingly, aberrant expression of LOX-like 2 (LOXL2) is observed in poorly differentiated, high-grade tumors and is predictive of diseases recurrence, and for decreased overall patient survival. Therefore, LOXL2 expression may serve as a biomarker for breast cancer. Mechanistically, hydrogen peroxide is produced as a byproduct of LOXL2 when using an appropriate substrate, lysine. We exploited this chemistry to generate a revolutionary gold-based electrochemical biosensor capable of accurately detecting nanomolar quantities of LOXL2 in mouse blood, and in human blood samples. Two different sources of the blood samples obtained from breast cancer patients were used in this study indicating the applicability of detecting LOXL2 in breast cancers patients. Limited numbers of urine specimens from breast cancer patients were also tested. Collectively, all of these tests show the promise and potential of this biosensor for detecting LOXL2 as a surrogate biomarker of breast cancer. This work is described in patent number WO2014052962 (2014).

AB - Metastasis accounts for 90% of the mortality associated with breast cancer. Upregulated expression of members of the lysyl oxidase (LOX) family of secreted copper amine oxidases catalyzes the crosslinking of collagens and elastin in the extracellular matrix. LOXs are linked to the development and metastatic progression of breast cancers. Accordingly, aberrant expression of LOX-like 2 (LOXL2) is observed in poorly differentiated, high-grade tumors and is predictive of diseases recurrence, and for decreased overall patient survival. Therefore, LOXL2 expression may serve as a biomarker for breast cancer. Mechanistically, hydrogen peroxide is produced as a byproduct of LOXL2 when using an appropriate substrate, lysine. We exploited this chemistry to generate a revolutionary gold-based electrochemical biosensor capable of accurately detecting nanomolar quantities of LOXL2 in mouse blood, and in human blood samples. Two different sources of the blood samples obtained from breast cancer patients were used in this study indicating the applicability of detecting LOXL2 in breast cancers patients. Limited numbers of urine specimens from breast cancer patients were also tested. Collectively, all of these tests show the promise and potential of this biosensor for detecting LOXL2 as a surrogate biomarker of breast cancer. This work is described in patent number WO2014052962 (2014).

KW - Biomarker

KW - Lysyl oxidase-like 2 (LOXL2)

KW - Metastasis of breast cancers

KW - Thin gold film biosensor

UR - http://www.scopus.com/inward/record.url?scp=84977108202&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84977108202&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84977108202

VL - 5

SP - 93

EP - 100

JO - Current Biomarkers

JF - Current Biomarkers

SN - 2468-4228

IS - 2

ER -